Trials / Completed
CompletedNCT03116152
Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment
Efficacy and Safety Evaluation of IBI308 Versus Paclitaxel/Irinotecan in Patients With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment: a Randomized, Open-label, Multicenter, Phase 2 Study (ORIENT-2)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 190 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and safety evaluation of IBI308 versus paclitaxel/irinotecan in patients with advanced/metastatic esophageal squamous cell carcinoma after failure of first-line treatment: a randomized, open-label, multicenter, phase 2 study
Detailed description
Efficacy and safety evaluation of IBI308 versus paclitaxel/irinotecan in patients with advanced/metastatic esophageal squamous cell carcinoma after failure of first-line treatment: a randomized, open-label, multicenter, phase 2 study (ORIENT-2)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IBI308 | IBI308 200mg Intravenous drip every three weeks； |
| DRUG | paclitaxel/ irinotecan | paclitaxel 175mg/㎡ Intravenous drip every three weeks or irinotecan 180mg/㎡ Intravenous drip every two weeks |
Timeline
- Start date
- 2017-05-10
- Primary completion
- 2019-10-02
- Completion
- 2019-10-02
- First posted
- 2017-04-14
- Last updated
- 2021-02-03
- Results posted
- 2021-01-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03116152. Inclusion in this directory is not an endorsement.